Cargando…
Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria
This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219198/ https://www.ncbi.nlm.nih.gov/pubmed/37240667 http://dx.doi.org/10.3390/jcm12103561 |
_version_ | 1785048952217796608 |
---|---|
author | Bernstein, Jonathan A. Giménez-Arnau, Ana Maurer, Marcus Staubach, Petra Barbier, Nathalie Hua, Eva Severin, Thomas Laires, Pedro A. Balp, Maria-Magdalena |
author_facet | Bernstein, Jonathan A. Giménez-Arnau, Ana Maurer, Marcus Staubach, Petra Barbier, Nathalie Hua, Eva Severin, Thomas Laires, Pedro A. Balp, Maria-Magdalena |
author_sort | Bernstein, Jonathan A. |
collection | PubMed |
description | This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the dermatology life quality index (DLQI), and work productivity and activity impairment-chronic urticaria (WPAI-CU). The number of DLQI scores, weekly sleep interference scores (SIS7), weekly activity interference scores (AIS7), and overall work impairment (OWI) evaluations with a complete response per weekly urticaria activity score (UAS7) using bands (0, 1–6, 7–15, 16–27, and 28–42) were reported. Over 50% of the patients had a mean DLQI of > 10 at baseline, indicating a significant effect of chronic spontaneous urticaria (CSU) on their HRQoL. Complete response (UAS7 = 0) evaluations corresponded with no impacts on other patient-reported outcomes. In total, 91.1% of UAS7 = 0 evaluations corresponded to DLQI scores of 0–1, 99.7% to SIS7 scores of 0, 99.7% to AIS7 scores of 0, and 85.3% to OWI scores of 0. This was significantly different compared with the UAS7 = 1–6 evaluations (61.9%, 68.5%, 67.7%, and 65.4%, respectively; p < 0.0001). Complete responses to treatment were associated with no impairments on the dermatology-QoL, no interferences with sleep and activity, and significantly improved capacities to work compared to patients who continued to have signs and symptoms, even for those with minimal disease activity. |
format | Online Article Text |
id | pubmed-10219198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102191982023-05-27 Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria Bernstein, Jonathan A. Giménez-Arnau, Ana Maurer, Marcus Staubach, Petra Barbier, Nathalie Hua, Eva Severin, Thomas Laires, Pedro A. Balp, Maria-Magdalena J Clin Med Article This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the dermatology life quality index (DLQI), and work productivity and activity impairment-chronic urticaria (WPAI-CU). The number of DLQI scores, weekly sleep interference scores (SIS7), weekly activity interference scores (AIS7), and overall work impairment (OWI) evaluations with a complete response per weekly urticaria activity score (UAS7) using bands (0, 1–6, 7–15, 16–27, and 28–42) were reported. Over 50% of the patients had a mean DLQI of > 10 at baseline, indicating a significant effect of chronic spontaneous urticaria (CSU) on their HRQoL. Complete response (UAS7 = 0) evaluations corresponded with no impacts on other patient-reported outcomes. In total, 91.1% of UAS7 = 0 evaluations corresponded to DLQI scores of 0–1, 99.7% to SIS7 scores of 0, 99.7% to AIS7 scores of 0, and 85.3% to OWI scores of 0. This was significantly different compared with the UAS7 = 1–6 evaluations (61.9%, 68.5%, 67.7%, and 65.4%, respectively; p < 0.0001). Complete responses to treatment were associated with no impairments on the dermatology-QoL, no interferences with sleep and activity, and significantly improved capacities to work compared to patients who continued to have signs and symptoms, even for those with minimal disease activity. MDPI 2023-05-19 /pmc/articles/PMC10219198/ /pubmed/37240667 http://dx.doi.org/10.3390/jcm12103561 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bernstein, Jonathan A. Giménez-Arnau, Ana Maurer, Marcus Staubach, Petra Barbier, Nathalie Hua, Eva Severin, Thomas Laires, Pedro A. Balp, Maria-Magdalena Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title | Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title_full | Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title_fullStr | Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title_full_unstemmed | Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title_short | Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria |
title_sort | why a complete response is the treatment aim in chronic spontaneous urticaria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219198/ https://www.ncbi.nlm.nih.gov/pubmed/37240667 http://dx.doi.org/10.3390/jcm12103561 |
work_keys_str_mv | AT bernsteinjonathana whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT gimenezarnauana whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT maurermarcus whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT staubachpetra whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT barbiernathalie whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT huaeva whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT severinthomas whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT lairespedroa whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria AT balpmariamagdalena whyacompleteresponseisthetreatmentaiminchronicspontaneousurticaria |